Wikiwand AI

Anvumetostat

Investigational drug From Wikipedia, the free encyclopedia

Anvumetostat is an investigational new drug that is being developed by Amgen for the treatment of methylthioadenosine phosphorylase (MTAP)-null solid tumors.[1] Anvumetostat acts as a PRMT5 inhibitor.[2][3][4][5]

Other namesAMG-193
CAS Number
Quick facts Clinical data, Other names ...
Anvumetostat
INN: anvumetostat
Clinical data
Other namesAMG-193
Identifiers
  • (4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridin-8-yl)-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]methanone
CAS Number
PubChem CID
UNII
ChEMBL
PDB ligand
Chemical and physical data
FormulaC22H19F3N4O3
Molar mass444.414 g·mol−1
3D model (JSmol)
  • C1COC[C@@H](N1C(=O)C2=NC=C3C(=C2)C4=C(COC4)C(=N3)N)C5=CC=C(C=C5)C(F)(F)F
  • InChI=InChI=1S/C22H19F3N4O3/c23-22(24,25)13-3-1-12(2-4-13)19-11-31-6-5-29(19)21(30)17-7-14-15-9-32-10-16(15)20(26)28-18(14)8-27-17/h1-4,7-8,19H,5-6,9-11H2,(H2,26,28)/t19-/m1/s1
  • Key:BFEBTMFPRJPBTK-LJQANCHMSA-N
Close

References

Related Articles

Timelines

Top Qs

Fact Checks